Pregnancy-Specific Glycoproteins Bind Integrin αIIbβ3 and Inhibit the Platelet-Fibrinogen Interaction. by Shanley, Daniel K et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Molecular and Cellular Therapeutics Articles Department of Molecular and Cellular Therapeutics
1-1-2013
Pregnancy-Specific Glycoproteins Bind Integrin
αIIbβ3 and Inhibit the Platelet-Fibrinogen
Interaction.
Daniel K. Shanley
University College Cork
Patrick K. Kiely
University of Limerick
Kalyan Golla
Royal College of Surgeons in Ireland
Seamus Allen
Royal College of Surgeons in Ireland
Kenneth Martin
University College Cork
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Molecular and Cellular Therapeutics at e-publications@RCSI. It has
been accepted for inclusion in Molecular and Cellular Therapeutics Articles
by an authorized administrator of e-publications@RCSI. For more
information, please contact epubs@rcsi.ie.
Citation
Shanley DK, Kiely PA, Golla K, Allen S, Martin K, O'Riordan RT, Ball M, Aplin JD, Singer BB, Caplice N, Moran N, Moore M.
Pregnancy-Specific Glycoproteins Bind Integrin αIIbβ3 and Inhibit the Platelet-Fibrinogen Interaction. PLoS One. 2013;8(2):e57491
Authors
Daniel K. Shanley, Patrick K. Kiely, Kalyan Golla, Seamus Allen, Kenneth Martin, Ronan T. O'Riordan,
Melanie Ball, John D. Aplin, Bernhard B. Singer, Noel Caplice, Niamh Moran, and Tom Moore
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/mctart/53
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/mctart/53
Increased platelet counts and platelet activation in early symptomatic versus 
asymptomatic carotid stenosis and relationship with microembolic status:  
Results from the Platelets And Carotid Stenosis (PACS) Study 
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Abstract 
Background: Cerebral microembolic signals (MES) may predict increased stroke risk 
in carotid stenosis. However, the relationship between platelet counts or platelet 
activation status and MES in symptomatic versus asymptomatic carotid stenosis has 
not been comprehensively assessed. 
Setting: University teaching hospitals. 
Methods: This prospective, pilot observational study assessed platelet counts and 
platelet activation status, and the relationship between platelet activation and MES in 
asymptomatic versus early (≤4 weeks after TIA/stroke) and late phase (≥3 months) 
symptomatic moderate or severe (≥50%) carotid stenosis patients. Full blood count 
measurements were performed, and whole blood flow cytometry was used to quantify 
platelet surface activation marker expression (CD62P and CD63) and circulating 
leucocyte-platelet complexes. Bilateral simultaneous transcranial Doppler ultrasound 
monitoring of the middle cerebral arteries was performed for 1 hour to classify 
patients as MES-positive or MES-negative. 
Results: Data from 31 asymptomatic patients were compared with 46 symptomatic 
patients in the early phase, and 35 of these patients followed up to the late phase after 
symptom onset. The median platelet count (211 vs. 200 x 10
9
/L; p=0.03) and the 
median % lymphocyte-platelet complexes were higher in early symptomatic than 
asymptomatic patients (2.8 vs. 2.4%, p=0.001). The % lymphocyte-platelet complexes 
was higher in early symptomatic than asymptomatic patients with ≥70% carotid 
stenosis (p=0.0005), and in symptomatic patients recruited within 7 days of symptom 
onset (p=0.028). Complete TCD data were available in 25 asymptomatic and 31 early 
phase symptomatic, and 27 late phase symptomatic patients. 12% of asymptomatic 
versus 32% of early phase symptomatic (p=0.02) and 19% of late phase symptomatic 
patients (p=0.2) were MES-positive. Early symptomatic MES-negative patients had a 
higher % lymphocyte-platelet complexes than asymptomatic MES-negative patients 
(2.8 vs. 2.3%; p=0.0085).  
Discussion: Recently symptomatic carotid stenosis patients have higher platelet 
counts (potentially reflecting increased platelet production, mobilisation or reduced 
clearance) and platelet activation status than asymptomatic patients. MES were more 
frequently detected in early symptomatic than asymptomatic patients, but the 
differences between late symptomatic and asymptomatic groups were not significant. 
Increased lymphocyte-platelet complex formation in recently symptomatic vs. 
asymptomatic MES-negative patients indicates enhanced platelet activation in this 
early symptomatic subgroup. Platelet biomarkers, in combination with TCD, have the 
potential to aid risk-stratification in asymptomatic and symptomatic carotid stenosis 
patients. 
Introduction 
The two-year risk of stroke in the territory supplied by a severely stenosed (≥70%) 
internal carotid artery has decreased over the years from 4% [1] to 0.7-1.7% in >50% 
asymptomatic patients treated with best medical therapy,[2-4] but is reported to be as 
high as 26% in symptomatic patients with recent TIA or stroke treated with best 
medical therapy alone.[5] This disparity in risk may relate to differences in 
morphology and/or stability of the atherosclerotic plaque,[6] different degrees of 
endothelial and/or platelet activation, or differences in thrombogenicity of the 
circulating blood.[7] Excessive platelet activation could predispose to carotid plaque 
‘activation’ or thromboembolism from an activated plaque, which could contribute to 
the high risk of recurrent stroke in recently symptomatic patients; however, there are 
only limited pilot data available on this topic.[6;8;9;10]. 
Prior studies have illustrated the potential role of microembolic signals (MES) 
detected on transcranial Doppler ultrasound (TCD), and carotid plaque imaging in 
identifying asymptomatic and symptomatic carotid stenosis patients who may benefit 
from best medical rather than surgical therapy.[11-14] The ACES study found that 
MES could be used to identify patients with ≥70% asymptomatic carotid stenosis at 
highest risk of TIA or stroke.[15] TCD has also been used to assess the impact of 
different antiplatelet regimens on MES in patients with extracranial or intracranial 
arterial stenosis.[16;17] The CARESS study demonstrated that short-term aspirin and 
clopidogrel combination therapy reduced the incidence of MES on TCD compared 
with aspirin alone in patients with recently symptomatic ≥50% carotid stenosis 
(relative risk reduction 39.8%; p=0.0046).[17] These studies illustrate that TCD may 
identify asymptomatic carotid stenosis patients who warrant intervention, and the 
limited available data suggest that TCD has the potential to predict the response to 
antiplatelet regimens in the clinical setting. Other studies have also demonstrated the 
potential importance of statin therapy in reducing the risk of cerebrovascular events in 
patients with carotid stenosis [18,19], but the impact of statins on platelet activation 
status and MES is unknown. 
 
The primary aims of this component of the Platelets And Carotid Stenosis (PACS) 
study were to determine whether platelet counts or platelet activation markers were 
increased in patients with recently symptomatic vs. asymptomatic carotid stenosis, to 
assess whether recently symptomatic carotid patients had more MES on TCD than 
those with asymptomatic carotid stenosis, and to assess the impact of time from 
symptom onset and carotid intervention on platelet activation and MES status. We 
hypothesised that platelet counts or platelet activation markers, and the incidence of 
MES would be higher in symptomatic than asymptomatic patients, and that these 
parameters would decrease over time from symptom onset or carotid intervention. 
Methods 
Consecutive eligible patients >18 years old with asymptomatic or symptomatic 
moderate or severe carotid artery stenosis or carotid occlusion, identified on colour 
Doppler ultrasound (CDUS) using standardised velocity criteria,[20;21] were invited 
to participate between August 2007 and February 2010. Patients were recruited from 
the Rapid Access Stroke Prevention clinics, vascular surgery and general neurology 
clinics, stroke service, and neurology and vascular surgery wards. The study was 
approved by the St James Hospital / AMNCH local research ethics committee. 
Written informed consent (or assent) was obtained in all cases. 
 
Inclusion/Exclusion Criteria 
Patients were included in the ‘asymptomatic carotid stenosis’ group if incidentally 
noted to have moderate (50-69%) or severe (≥70%) carotid stenosis on screening 
CDUS e.g. following auscultation of a carotid bruit, during pre-operative work-up for 
another cause, or during vascular work-up in the vascular surgery or other clinics. 
Patients were deemed asymptomatic if they had never had a prior TIA or stroke, or 
had not had a TIA or stroke in the ipsilateral carotid or any other cerebrovascular 
territory within the preceding three years.  
Patients were included in the ‘symptomatic carotid stenosis’ group if they had a 
TIA or ischaemic stroke in the vascular territory supplied by a moderate or severe 
carotid stenosis or occlusion within the preceding 4 weeks (early phase), with 
symptoms attributed to the carotid artery of interest according to the TOAST 
classification. Patients with carotid occlusion were only included if no other cause for 
TIA or stroke was identified. These patients were prospectively reassessed ≥3 months 
after symptom onset or after surgical or endovascular intervention (late phase). 
 Exclusion criteria for all asymptomatic and symptomatic patients included active 
infection, inflammation or neoplasia; platelet count <120 or >450 x 10
9
/L; myocardial 
infarction, pulmonary embolism, deep vein thrombosis or major surgery within the 
preceding 3 months; prior primary intracerebral haemorrhage; known bleeding or 
clotting diathesis; ongoing unstable coronary or peripheral arterial disease; renal 
impairment (urea >10 mmol/l); or non-steroidal anti-inflammatory drug (NSAID) 
intake other than prescribed aspirin within the preceding 2 weeks. Patients were 
subsequently excluded from the symptomatic group if a potential cardioembolic 
source of embolism was detected within 3 months of recruitment. Patients were also 
excluded from the symptomatic group if they had symptoms, signs or subsequent 
neuro-imaging evidence of acute cerebral ischaemia outside the vascular territory 
supplied by the stenosed carotid artery of interest. 
 
Clinical Assessment 
All patients underwent detailed clinical and neurovascular assessment by a neurology 
research resident (JAK or WOT) or supervising consultant vascular neurologist 
(DJHM) to confirm that all inclusion/exclusion criteria were satisfied. Information 
regarding vascular risk factors, medication intake (including anti-thrombotic therapy), 
smoking status, alcohol intake, and the method of detection of carotid stenosis was 
collected prospectively. If antiplatelet therapy was altered by their treating physician 
in the early phase after presentation, patients were invited to undergo repeat blood 
testing 14 +/- 7 days later if they had not undergone carotid intervention by that stage. 
CT of brain and/or MRI of brain was performed in all symptomatic patients, and 
magnetic resonance angiography (MRA) or CT angiography (CTA) was performed 
where deemed appropriate by the treating physician to establish concordance between 
CDUS and another non-invasive imaging modality. 
 
Blood sampling and platelet studies 
All subjects were rested for ≥20 minutes, and venepuncture performed from a free-
flowing vein using a 21G butterfly needle and a Vacutainer
®
 system with a luer 
adaptor, as previously described.[22] After drawing an initial EDTA-anticoagulated 
sample, seven further 3ml samples were collected into 3.2% citrate-anticoagulated 
Vacutainer tubes. The first 3ml citrate-anticoagulated sample was used for whole 
blood flow cytometric analysis on a Beckman Coulter XL MCL flow cytometer. 
Platelets were distinguished from white and red cells by their characteristic forward 
and side scatter patterns, and by ensuring that >95% of cells expressed GpIbα 
(CD42b).[22] Platelet activation was assessed by quantifying platelet surface CD62P 
and CD63 expression [7;8;22] ≤ 90 minutes of venepuncture,[22] and the percentages 
of circulating neutrophil–platelet, monocyte–platelet, and lymphocyte–platelet 
complexes ≤ 3 hours of venepuncture.[7;22] using previously described [22] and 
validated methodology.[6;22] The next 5 tubes were used to prepare platelet poor 
plasma (stored at -80
o
C for prospective studies). The seventh citrate-anticoagulated 
sample was processed to measure platelet count, MPV and PDW in citrate-
anticoagulated blood between 2 and 4 hours after venepuncture on a Sysmex XE-2100 
haematology analyser (Sysmex UK Ltd.). 
 
Transcranial Doppler ultrasound 
TCD was performed by one of two highly-experienced operators (JAK or WOT) with 
a Viassys Pioneer TC8080. Each recording was performed with a 2-MHz probe, and 
usually included a sample volume (SV) of 5-8mm, although in some instances, a SV 
>8mm was used. We used a constant sweep speed of 5.1 seconds, and 128-point fast-
Fourier transform (FFT) spectral analysis, giving an overlap of >50%. Depth of 
insonation was 50-60 mm. Spontaneous MES detected in each middle cerebral artery 
(MCA) were recorded and quantified during a 1-hour period [23;24] according to 
published criteria.[25;26] The Doppler audio signal was recorded on the hard drive 
and recordings subsequently analysed ‘off-line’ by one experienced investigator 
blinded to patient details (JAK). MES were identified by their typical appearance 
within the spectral display and their characteristic high-pitched, chirping sound, using 
an intensity threshold of > 7dB.[25;26] Symptomatic patients were classified as 
‘MES-positive’ if they had ≥ 1 MES detected ipsilateral to the stenosed carotid artery 
of interest. Asymptomatic patients were considered ‘MES-positive’ if ≥ 1 MES was 
detected ipsilateral to an asymptomatic ≥50% carotid stenosis. Other patients were 
deemed ‘MES-negative’. If symptomatic patients did not undergo surgical or 
endovascular intervention, they were reassessed >3 months after symptom onset. Any 
patients who underwent intervention were reassessed >3 months following 
intervention. Full blood count (FBC) and platelet activation measurements were 
performed within 24 hours of TCD recordings.[7;22] 
 
Statistical Analysis 
Paired or unpaired t-tests were used for comparison of paired and unpaired parametric 
variables, respectively, the Wilcoxon signed rank test and the Wilcoxon rank sum test  
for comparison of paired and unpaired non-parametric variables, and the Kruskal-
Wallis rank sum test for comparison of multiple non-parametric variables, where 
appropriate. Chi-squared or Fisher exact tests compared proportions between groups. 
Multiple linear regression analysis was performed to investigate the potential 
inﬂuence of independent demographic or vascular risk factors on any observed 
differences between groups, where appropriate. Approximately 10% of recordings 
were also analysed by an experienced, independent observer (MS) blinded to clinical 
details, symptomatic status, and recorded MES status of the study subjects, to validate 
the accuracy of TCD data collected at our centre. Inter-observer agreement between 
JK and MS in the assessment of ‘emboli-positive’ patients (those with ≥1 MES) was 
calculated with Cohen’s unweighted kappa statistic (κ) [27]. P < 0.05 was considered 
statistically significant. All statistical calculations were performed with R version 
2.9.1.[28] 
Results 
31 asymptomatic and 61 recently symptomatic carotid stenosis patients initially had 
platelet activation data available for analysis. Figure 1 outlines details of symptomatic 
patients subsequently excluded from analysis; therefore, we included data from 46 
early phase symptomatic patients, and from 35 of these patients followed up to the 
late phase after symptoms, 23 of whom had undergone carotid intervention (Table 1). 
22 late symptomatic patients had undergone carotid endarterectomy, one had carotid 
stenting, 7 declined surgical intervention or chose optimal medical management and 5 
had carotid occlusion. Two of the post-intervention group developed 50–69% carotid 
restenosis, and one developed >70% restenosis on repeat CDUS at least 3 months 
after endarterectomy, but none experienced recurrent symptoms before follow-up. Of 
the 23 early symptomatic patients who presented with stroke, the median NIHSS 
score among this group was 1 (range: 0 – 17). 
 
Platelet activation status and platelet parameters: 
The median platelet count in citrate-anticoagulated whole blood was higher in early 
symptomatic than asymptomatic patients (211 vs. 200 x 10
9
/L; p=0.03, Table 2). 
There were no differences in CD62P or CD63 expression, or % neutrophil-platelet or 
monocyte-platelet complexes between asymptomatic and symptomatic patients (Table 
2). However, median % lymphocyte-platelet complexes was higher in early 
symptomatic than asymptomatic patients (2.8 vs. 2.4%; p=0.001, Table 2). After 
controlling for differences in the prevalence of hypertension, statin use and smoking 
between groups, the median platelet count (p=0.045) and median % lymphocyte-
platelet complexes (p=0.037) remained higher in early symptomatic than 
asymptomatic patients. 
Twenty-five asymptomatic patients, and 31 early and 27 late symptomatic patients 
had TCD data available for analysis (Table 3a). Twenty-two symptomatic patients had 
longitudinal TCD data available at both early and late phases. Inter-observer 
agreement in assessing the presence or absence of MES between JK and MS was 
excellent (93% concordance, κ = 0.89), strongly supporting the validity of our 
remaining data analysis performed on site. 
Three (12%) asymptomatic patients vs. 32% early symptomatic (p = 0.02) and 19% 
late symptomatic patients (p = 0.2) were MES-positive (Table 3a). Amongst the 3 
asymptomatic MES-positive patients, 2 had >50% stenosis, and the third had 
complete carotid occlusion with contralateral severe stenosis with MES detected distal 
to the occlusion. There were no statistically significant differences in the incidence of 
MES between asymptomatic patients (12%) and subgroups of late phase symptomatic 
patients who did (3/19 [16%], p=0.35) and did not undergo carotid intervention (2/8 
[25%], p=0.19). Amongst symptomatic patients with longitudinal data at both phases 
after symptom onset, there was a non-significant trend towards a reduction in the 
incidence of MES between the early and late phases (36% vs. 23%; p=0.17). 
Platelet count and activation status in MES-positive and MES-negative subgroups 
There were no significant differences in platelet counts or activation markers between 
early or late symptomatic and asymptomatic MES-positive subjects. However, the 
median platelet count (191 vs. 172 x 10
9
/L; p=0.013) and % lymphocyte-platelet 
complexes (2.78 vs. 2.29%; p=0.0085) were higher in early symptomatic than 
asymptomatic MES-negative patients. Having controlled for differences in smoking 
prevalence between early symptomatic MES-negative and asymptomatic MES-
negative patients, differences in platelet counts (p=0.035) and % lymphocyte-platelet 
complexes (p=0.02) persisted between subgroups. 
Pre-planned subgroup analyses: 
Because different antiplatelet regimens could potentially have influenced observed 
differences in platelet activation status between asymptomatic and symptomatic 
patients (Table 1), pre-planned subgroup analysis was performed in patients on aspirin 
monotherapy. The % lymphocyte-platelet complexes remained higher in early 
symptomatic than asymptomatic patients on aspirin monotherapy (p=0.013). CD63 
expression was slightly lower in late symptomatic than asymptomatic patients on 
aspirin (p=0.048).  
Median % lymphocyte-platelet complexes was also elevated in early symptomatic 
(n=33) versus asymptomatic severe (≥70%) carotid stenosis (n=20; 2.86% vs. 2.43%, 
p=0.0005). Otherwise, there were no other significant differences in platelet activation 
between early or late symptomatic versus asymptomatic severe carotid stenosis 
patients (p≥0.1).  
% lymphocyte-platelet complexes was also higher in early symptomatic patients who 
had TIA or stroke ≤7 days of study inclusion (n=23) than asymptomatic patients (2.8 
vs. 2.4%; p=0.028). 
There were no changes in platelet count, MPV, PDW or platelet activation over time, 
or after carotid intervention in the symptomatic patient subgroup with follow-up data 
at each timepoint (P > 0.22). However, the number of subjects included in these 
subgroup analyses was limited. 
Discussion 
The finding of a higher platelet count in early symptomatic versus asymptomatic 
moderate or severe carotid stenosis may indicate enhanced platelet production, 
platelet secretion or reduced clearance early after TIA or stroke, and is in keeping 
with the findings of a smaller pilot study in a similar population with severe carotid 
stenosis.[7] The lack of significant differences in platelet counts between late phase 
symptomatic and asymptomatic patients could reflect resolution of the acute phase 
response during prolonged clinical follow-up or following intervention, or could 
reflect a type II error because only 35/46 symptomatic patients had late phase data, 
and overall study numbers were relatively small. Our longitudinal subgroup data 
suggest that this study was probably underpowered to detect changes between late 
symptomatic (n=35) and asymptomatic patients (n=31) because the platelet count and 
platelet activation status did not decrease significantly during follow-up in the 
subgroup of symptomatic patients assessed in both the early and late phases after TIA 
or stroke onset, or before and after carotid intervention. 
Elevated leucocyte–platelet complexes have previously been reported in a pilot study 
in severe symptomatic versus asymptomatic carotid stenosis.[7] Our subgroup 
analysis that revealed elevated lymphocyte-platelet complexes in early symptomatic 
versus asymptomatic severe carotid stenosis is consistent with these data.[7] The 
concurrent findings of increased platelet counts and lymphocyte-platelet complexes 
may reflect pre-existing excessive platelet production/secretion and activation, or 
could have arisen secondary to acute ocular or cerebral ischaemia/infarction early 
after TIA or stroke in patients with recently symptomatic carotid stenosis compared 
with their asymptomatic counterparts. Platelets and leucocytes may have excitatory 
effects on one another, with leucocyte-platelet complex formation facilitating 
interaction between the two cell types.[29;30] The formation of leucocyte-complexes 
may increase the risk of thrombus formation or plaque inflammation, and predispose 
to recurrent cerebrovascular events due to embolism from the thrombotic milieu of an 
activated plaque in symptomatic patients.  
Our study suggests that measurement of % leucocyte-platelet complexes with 
unstimulated whole blood flow cytometry is a more sensitive method of assessing 
platelet activation status than measurement of %CD62P or CD63 expression. 
However, a cross-sectional and case-control study found elevated soluble P-selectin, 
and surface CD62P and CD63 expression in symptomatic >70% compared with 
asymptomatic >50% carotid stenosis patients (p < 0.05).[9] The apparent disparity in 
results between this study and ours may reflect differences in demographic profiles, 
antithrombotic therapy, time from symptom onset and stenosis severity in the 
symptomatic groups, and differences in methodology employed to quantify leucocyte-
platelet complexes. However, each study provides important evidence of enhanced 
platelet activation in symptomatic vs. asymptomatic carotid stenosis. 
Only 50% of early symptomatic patients experienced symptoms within one week of 
enrolment, and the remainder were recruited over the subsequent 3 weeks after TIA or 
stroke. The % lymphocyte-platelet complexes may have been predominantly 
increased due to binding of activated platelets to more ‘chronic inflammatory’ 
leucocytes i.e. lymphocytes, with less pronounced binding to more ‘hyperacute-phase’ 
leucocytes, such as neutrophils or monocytes during the initial 4 week recruitment 
period, but this hypothesis is speculative. There are no data available on the precise 
half-life of individual leucocyte-platelet complexes in vivo in humans. Marquardt et 
al. assessed leucocyte-platelet complexes in 45 patients within 24 hours of ischaemic 
stroke and compared these data with 30 healthy age- and sex-matched controls.[31] 
Neutrophil-platelet complexes were elevated from days 1 – 10, and monocyte-platelet 
complexes on day 2 following stroke in patients versus controls. Lymphocyte-platelet 
complexes were not elevated at any time point up to 90 days after symptoms in 
patients versus controls. 
Prior to this study, published data supported the concept that MES predict subsequent 
TIA or ischaemic stroke risk in patients with >60% [11-14] and ≥70% asymptomatic 
carotid artery stenosis.[15;32] However, to our knowledge, no studies compared both 
platelet counts, platelet activation status and MES in asymptomatic versus recently 
symptomatic ≥50% carotid stenosis, and symptomatic patients followed up to the late 
phase after symptoms or intervention. There are no data, to our knowledge, 
comparing MES status in late phase symptomatic versus asymptomatic carotid 
stenosis patients. 
Ritter et al. found higher soluble P-selectin levels in patients with >50% 
asymptomatic carotid stenosis with MES versus those without MES (p=0.0007).[33] 
However, platelet surface CD62P expression was actually lower in MES-positive than 
MES-negative patients with recent atherothrombotic stroke (p=0.004). In our study, 
MES were significantly more common in early symptomatic than asymptomatic 
patients, but the difference between late symptomatic and asymptomatic patients was 
non-significant. These early phase data are in keeping with the subgroup analysis in 
an earlier study in asymptomatic versus symptomatic patients within 3 months of TIA 
or stroke onset.[14] Our longitudinal, late-phase data may reflect successful treatment 
of the stenosing atheromatous plaque in 21/31 (68%) symptomatic patients during 
follow-up, with alteration of antiplatelet therapy [17;34;35] or ‘plaque healing’ in 
others. At the discretion of the treating physicians who referred patients for 
recruitment to this study, 44% of late symptomatic patients were treated with aspirin 
monotherapy, whereas others were treated with aspirin-dipyridamole combination 
therapy (30%), clopidogrel monotherapy (19%), and two patients were on aspirin-
clopidogrel combination therapy (Table 1). Because the principal researchers did not 
alter treatment in patients who were not directly under our care, we could not formally 
assess the impact of altering antiplatelet regimens on MES status. 
 
The absolute percentage of MES-positive patients was slightly lower in late 
symptomatic patients who underwent carotid intervention (16%) than those who did 
not (25%), but differences between these symptomatic subgroups were not significant. 
However, the number of subjects included in this post hoc analysis was far too small 
to make any definitive conclusions about the impact of endarterectomy on MES 
status. There is some evidence that ‘diffuse inflammation’ may occur in the vascular 
system, perhaps secondary to atherosclerotic plaque activation associated with a 
systemic inflammatory response,[36] and in patients with symptomatic carotid 
stenosis with contralateral <50% or >50% ‘clinically asymptomatic’ stenosis.[37] 
Activation of these ‘apparently clinically-silent plaques’ could lead to distal 
embolisation and detection of contralateral MES in some subjects. 
 
There were no significant differences in lymphocyte-platelet complexes between early 
symptomatic and asymptomatic MES-positive patients, perhaps reflecting the fact that 
these patients may have similarly elevated levels of platelet activation secondary to 
MES formation. Platelet counts and lymphocyte-platelet complex formation were 
higher in early symptomatic than asymptomatic MES-negative patients, also 
potentially indicative of increased platelet production, secretion or reduced clearance, 
and increased platelet activation in this early symptomatic subgroup. These data 
confirm that platelets may be excessively activated in subgroups of symptomatic 
patients who do not have detectable emboli on TCD.  
 
Further prospective studies are warranted to determine whether a multimodal risk-
stratification model, including MES detection and concurrent platelet count/activation 
assessment, especially with quantification of leucocyte-platelet complexes, has the 
potential to identify carotid stenosis patients at highest risk of recurrent events who 
need urgent medical or surgical intervention. 
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Table 1: Demographic and vascular risk factor profile of patients with platelet activation data. P 
values relate to chi-squared or Fisher exact testing between asymptomatic and symptomatic 
carotid stenosis groups. Values are means (±Standard deviation) or absolute values. TIA = 
Transient Ischaemic Attack; PE = Pulmonary embolism; DVT = Deep vein thrombosis. 
Parameter Asymptomatic 
(n = 31) 
Early Symptomatic 
(n=46) 
Late Symptomatic 
(n=35) 
Mean age (years) 68.2 [± 7.95] 65.0 [± 9.58] 65.0 [±9.9] 
P-value  0.78 0.78 
Sex (Male; %) 18 (58%) 28 (61%) 20 (57%) 
P-value  0.8 0.94 
Median Interval from Symptom 
Onset (days; range) 
N/A 7.5 (0 - 27) 175 (99 – 360) 
Degree of Stenosis:    
   Moderate: ≥50–69% 11 (35%) 7 (15%) 15 (43%) 
P-value  0.039 0.54 
   Severe: ≥ 70–99% 20 (65%) 33 (72%) 9 (26%) 
P-value  0.50 0.0015 
   Occlusion 0 6 (13%) 4 (11%) 
P-value  0.04 0.07 
Antiplatelet Therapy:    
- Aspirin monotherapy 22 (71%) 35 (76%) 15 (43%) 
P-value  0.62 0.02 
- Aspirin / Dipyridamole 
combination 
2 (6%) 4 (9%) 11 (31%) 
P-value  0.54 0.01 
- Clopidogrel monotherapy 5 (16%) 2 (4%) 6 (17%) 
P-value  0.09 0.6 
- Aspirin /Clopidogrel combination 2 (6%) 5 (11%) 3 (9%) 
P-value  0.4 0.6 
Ischemic Heart Disease 7 (23%) 10 (22%) 7 (20%) 
P-value  0.93 0.8 
Hypertension 27 (87%) 29 (63%) 23 (66%) 
P-value  0.02 0.04 
Diabetes Mellitus 7 (23%) 8 (17%) 6 (17%) 
P-value  0.57 0.58 
Prior TIA/Stroke 8 (26%) 7 (15%) 6 (17%) 
P-value  0.25 0.39 
Prior DVT/PE 1 (3%) 0 0 
P-value  0.4 0.5 
Peripheral Vascular Disease  5 (16%) 5 (11%) 6 (17%) 
P-value  0.5 0.91 
Migraine (with or without aura) 6 (19%) 5 (11%) 5 (14%) 
P-value  0.3 0.58 
Family History of Stroke 9 (29%) 16 (35%) 12 (34%) 
P-value  0.6 0.65 
Current smoker 5 (16%) 21 (46%) 14 (40%) 
P-value  0.007 0.03 
Ex-smoker 22 (71%) 17 (37%) 13 (37%) 
P-value  0.003 0.006 
Never Smoker 4 (13%) 8 (17%) 8 (23%) 
P-value  0.59 0.3 
Statin Therapy 28 (90%) 33 (72%) 27 (77%) 
P-value  0.043 0.13 
Table 2: Platelet activation markers and platelet count in asymptomatic versus early and late 
symptomatic carotid stenosis subjects. Values are medians (25th - 75th percentile). P values refer 
to comparison between asymptomatic and symptomatic groups. 
 Marker Asymptomatic (n=31) Early Symptomatic (n=46) Late Symptomatic (n=35) 
%CD62P 1.97 (1.19 – 2.44) 1.88 (1.29 – 2.5) 1.87 (1.31 – 2.76) 
p   0.88 0.46 
%CD63 11.0 (8.86 – 15.6) 9.78 (7.86 – 15.6) 10.1 (7.6 – 12.7) 
p  0.64 0.1 
% Neutrophil-Platelet Complexes 2.72 (2.4 – 3.1) 2.9 (2.5 – 3.4) 2.76 (2.4 – 3.4) 
p  0.22 0.53 
% Monocyte-Platelet Complexes 4.6 (4.3 – 5.6) 5.5 (4.0 – 6.8) 5.0 (4.1 – 5.9) 
p  0.3 0.69 
% Lymphocyte-Platelet Complexes 2.4 (1.8 – 2.7) 2.8 (2.4 – 3.3) 2.5 (2.2 – 3.0) 
p  0.001 0.21 
Platelet Count (x109/L) (Citrate) 200 (179 – 217) 211 (187 – 273) 219 (167 – 255) 
p  0.03 0.10 
Table 3a: Demographic data and risk factor profiles of study patients with TCD data. P values 
relate to chi-squared or Fisher exact tests between asymptomatic versus early or late 
symptomatic carotid stenosis patients. Values are means (±Standard deviation) or absolute 
counts, with percentages in square parentheses, where appropriate. MES = Microembolic 
Signals; TIA = Transient Ischaemic Attack; PE = Pulmonary embolism; DVT = Deep vein 
thrombosis. 
Parameter Asymptomatic 
(n = 25) 
Early Symptomatic 
(n=31) 
Late Symptomatic 
(n=27) 
Mean age (years) 69 (±7.8) 65.6 (±9.8) 64.9 (±10.4) 
P-Value  0.2 0.14 
Sex (Male [%]) 17 (68%) 23 (74%) 19 (70%) 
P-Value  0.61 0.85 
Degree of Stenosis:    
...Moderate, 50–69% 8 (32%) 4 (13%) 5 (19%) 
P-Value  0.11 0.34 
...Severe, 70 – 99% 17 (68%) 24 (77%) 2 (7%) 
P-Value  0.43 < 0.001 
…Occlusion 0 3 (10%) 3 (11%) 
P-Value  0.25 0.24 
No of patients who were MES+ (%)    
…Ipsilateral to carotid stenosis of interest 3 (12%) 10 (32%) 5 (19%) 
P-Value  0.02 0.2 
   <50% stenosis 2 (8%)  0 3 (11%) 
P-Value  0.2 1.0 
   Moderate stenosis ≥50–69% 0 0 1 (4%) 
P-Value  1.0 1.0 
   Severe stenosis ≥ 70–99% 0 9 (29%) 0 
P-Value  0.003 1.0 
   Occlusion 1 (4%) 1 (3%) 1 (4%) 
P-Value  1 1.0 
Contralateral to carotid stenosis of 
interest 
0 5 (16%) 3 (11%) 
P-Value  0.058 0.24 
-Bilateral MES 0 3 (10%) 1 (4%) 
P-Value  0.11 0.33 
Antiplatelet therapy    
- Aspirin monotherapy 16 (64%) 22 (71%) 12 (44%) 
P-Value  0.58 0.16 
- Aspirin-Dipyridamole combination Rx 2 (8%) 4 (13%) 8 (30%) 
P-Value  0.56 0.048 
- Clopidogrel monotherapy 5 (20%) 1 (3%) 5 (19%) 
P-Value  0.044 0.89 
- Aspirin-Clopidogrel combination Rx 2 (8%) 1 (3%) 2 (7%) 
P-Value  0.43 0.94 
Ischemic Heart Disease 6 (24%) 7 (23%) 5 (19%) 
P-Value  0.9 0.63 
Hypertension 22 (88%)  19 (61%) 17 (63%) 
P-Value  0.025 0.037 
Diabetes Mellitus 5 (20%) 5 (16%) 3 (11%) 
P-Value  0.71 0.37 
Prior TIA/Stroke 8 (32%) 5 (16%) 5 (19%) 
P-Value  0.16 0.26 
Prior DVT/PE 0 0 0 
P-Value  1.0 1.0 
Peripheral Vascular Disease 4 (16%) 6 (19%) 5 (19%) 
P-Value  0.74 0.81 
Migraine (with or without aura) 5 (20%) 4 (13%) 3 (11%) 
P-Value  0.49 0.46 
Family History of Stroke 8 (32%) 8 26%) 10 (37%) 
P-Value  0.61 0.7 
Current smoker 4 (16%) 15 (48%) 5 (19%) 
P-Value  0.013 1.0 
Ex-smoker 18 (72%) 12 (39%) 18 (67%) 
P-Value  0.013 0.68 
Never smoker 3 (12%) 4 (13%) 4 (15%) 
P-Value  0.92 0.77 
Statin therapy 24 (96%) 22 (71%) 26 (96%) 
P-Value  0.015 0.96 
 
Table 3b: Prescribed antiplatelet and statin therapy in MES-positive asymptomatic and early 
and late symptomatic carotid stenosis patients. Results are actual numbers with percentages in 
parentheses. 
Medication Asymptomatic (n=3) Early Symptomatic (n=10) Late Symptomatic (n=5) 
Aspirin monotherapy (75-300mg/d) 3 (100%) 9 (90%) 4 (80%) 
Aspirin-Dipyridamole combination 0 0 1 (20%) 
Clopidogrel monotherapy (75mg/d) 0 0 0 
Aspirin-Clopidogrel combination 0 0 0 
Statin Therapy (10-30mg) 2 (67%) 3 (30%) 5 (100%) 
                            (40mg) 1 (33%) 2 (20%) 0 
                            (80mg) 0 1 (10%) 0 
 
Table 3c: Prescribed antiplatelet and statin therapy in MES-negative asymptomatic and early 
and late symptomatic carotid stenosis patients. Results are actual numbers with percentages in 
parentheses. 
Medication Asymptomatic (n=22) Early Symptomatic (n=21) Late Symptomatic (n=22) 
Aspirin monotherapy (75-300mg/d) 13 (59%) 14 (67%) 8 (36%) 
Aspirin-Dipyridamole combination 2 (9%) 4 (19%) 7 (32%) 
Clopidogrel monotherapy (75mg/d) 5 (23%) 2 (10%) 5 (23%) 
Aspirin-Clopidogrel combination 2 (9%) 0 2 (9%) 
Statin Therapy (10-20mg) 11 (50%) 5 (24%) 11 (50%) 
                            (40-50mg) 9 (41%) 8 (38%) 7 (32%) 
                            (80mg) 1 (5%) 3 (14%) 3 (14%) 
Table 3d: Median markers of platelet activation and platelet count in early symptomatic versus 
asymptomatic MES-negative carotid stenosis patients 
 
Early Symptomatic MES-
negative (n=21) 
Asymptomatic 
MES-negative (n=22) P value 
CD62P % 1.87 (1.57 – 2.25) 1.81 (1.05 – 2.31) 0.47 
CD63 % 14.5 (8.84 – 15.7) 10.8 (8.54 – 13.93) 0.14 
% Neutrophil–platelet complexes  3.11 (2.26 – 3.54) 2.7 (2.4 – 3.1) 0.26 
% Monocyte–platelet complexes 4.95 (3.84 – 6.55) 4.6 (4.4 – 5.5) 0.99 
% Lymphocyte-platelet complexes  2.78 (2.49 – 3.36) 2.29 (1.8 – 2.6) 0.0085 
Platelet Count (x109/L) (Citrate) 191 (173 – 234) 172 (159 – 190) 0.013 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1: Algorithm of asymptomatic and symptomatic carotid stenosis patients screened and 
subsequently excluded from the study 
  
61 early symptomatic carotid stenosis 
subjects initially recruited 
46 early symptomatic subjects with complete 
platelet activation data and 31 early symptomatic 
subjects with complete TCD data 
Excluded: 
 5 with Paroxysmal AF 
 3 non-carotid territory infarction on 
DWI 
 4 < 50% ICA stenosis on other 
vascular imaging 
 3 symptoms > 4 weeks prior to 
enrolment 
 4 declined TCD 
 5 no temporal windows 
 6 with no usable TCD data 
Subjects initially followed up 
longitudinally to late phase 
Excluded: 
 6 declined repeat assessment 
 1 moved location 
 1 developed active symptomatic PVD 
 1 developed active ongoing gout 
 2 died from unrelated causes 
 3 declined repeat TCD 
 3 no temporal windows 
 2 had no data - equipment error 
35 late phase symptomatic subjects with 
complete platelet activation data and 27 
late phase symptomatic subjects with 
complete TCD data 
31 subjects with asymptomatic carotid 
stenosis initially enrolled 
Excluded: 
 3 no temporal windows 
 2 declined TCD 
 1 had no data - equipment error 
25 asymptomatic subjects with 
complete TCD data 
Reference List 
 
 1.  The European Carotid Surgery Trialists Collaborative Group: Risk of stroke in the distribution 
of an asymptomatic carotid artery. The European Carotid Surgery Trialists Collaborative Group. 
Lancet 1995;345:209-212. 
 2. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsilateral stroke in patients 
with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based 
study. Stroke. 2010;41:e11-e17. 
 3. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke 
associated with asymptomatic severe carotid stenosis: results of a systematic review and 
analysis. Stroke. 2009;40:e573-e583. 
 4. Naylor AR. Time to rethink management strategies in asymptomatic carotid artery disease. 
Nature Reviews Cardiology. 2012;9:116-24. 
 5.  North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of 
carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North 
American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 
1991;325:445-453. 
 6.  Golledge J, Greenhalgh RM, Davies AH: The symptomatic carotid plaque. Stroke 2000;31:774-
781. 
 7.  McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Purdy G, Lawrie AS, Watt H, Machin SJ, Brown 
MM: Increased platelet count and leucocyte-platelet complex formation in acute symptomatic 
compared with asymptomatic severe carotid stenosis. J Neurol Neurosurg Psychiatry 
2005;76:1249-1254. 
 8.  Cha JK, Jeong MH, Jang JY, Bae HR, Lim YJ, Kim JS, Kim SH, Kim JW: Serial measurement 
of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic 
ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. 
Cerebrovasc Dis 2003;16:376-382. 
 9.  Jurk K, Ritter MA, Schriek C, Van AH, Droste DW, Ringelstein EB, Kehrel BE: Activated 
monocytes capture platelets for heterotypic association in patients with severe carotid artery 
stenosis. Thromb Haemost 2010;103:1193-1202. 
 10. Kinsella JA, Tobin WO, Hamilton G, McCabe DJ. Platelet activation, function, and reactivity in 
atherosclerotic carotid artery stenosis: a systematic review of the literature. Int J Stroke. 2012 
Sep 27. [Epub ahead of print] 
 11.  Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG: Absence of microemboli on 
transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke 
2005;36:2373-2378. 
 12.  Spence JD, Coates V, Li H, Tamayo A, Munoz C, Hackam DG, Dicicco M, Desroches J, 
Bogiatzi C, Klein J, Madrenas J, Hegele RA: Effects of intensive medical therapy on 
microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol 
2010;67:180-186. 
 13.  Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD: High-risk asymptomatic carotid 
stenosis: ulceration on 3D ultrasound vs TCD microemboli. Neurology 2011;77:744-750. 
 14.  Molloy J, Markus HS: Asymptomatic embolization predicts stroke and TIA risk in patients with 
carotid artery stenosis. Stroke 1999;30:1440-1443. 
 15.  Markus HS, King A, Shipley M, Topakian R, Cullinane M, Reihill S, Bornstein NM, Schaafsma 
A: Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli 
Study (ACES): a prospective observational study. Lancet Neurol 2010:9, 663-671. 
 16.  Wong KSL, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn 
D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS: Clopidogrel plus aspirin versus aspirin alone 
for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis 
(CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurology 2010;9:489-
497. 
 17.  Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB: Dual 
antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using 
doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in 
Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-2240. 
 18. Amarenco P, Benavente O, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, Gilbert S, 
Rudolph AE, Simunovic L, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels Investigators. Results of the StrokePrevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405-9. 
 19. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid 
atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9. 
 20.  Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, Carroll BA, Eliasziw 
M, Gocke J, Hertzberg BS, Katanick S, Needleman L, Pellerito J, Polak JF, Rholl KS, Wooster 
DL, Zierler RE: Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of 
Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-346. 
 21.  Sidhu PS, Allan PL: Ultrasound assessment of internal carotid artery stenosis. Clin Radiol 
1997;52:654-658. 
 22.  McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Purdy G, Lawrie AS, Watt H, Brown MM, 
Machin SJ: Platelet degranulation and monocyte-platelet complex formation are increased in the 
acute and convalescent phases after ischemic stroke or transient ischemic attack. Br J Haematol 
2004;125:777-787. 
 23.  Molloy J, Khan N, Markus HS: Temporal variability of asymptomatic embolization in carotid 
artery stenosis and optimal recording protocols. Stroke 1998;29:1129-1132. 
 24.  Mackinnon AD, Aaslid R, Markus HS: Long-term ambulatory monitoring for cerebral emboli 
using transcranial Doppler ultrasound. Stroke 2004;35:73-78. 
 25.  Markus HS, Molloy J: Use of a decibel threshold in detecting Doppler embolic signals. Stroke 
1997;28:692-695. 
 26.  Bernd Ringelstein E, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, Markus HS, 
Russell D, Siebler M: Consensus on Microembolus Detection by TCD. Stroke 1998;29:725-729. 
 27.  Cohen J: Weighted kappa: nominal scale agreement with provision for scaled disagreement or 
partial credit. Psychol Bull 1968;70:213-220. 
 28.  R Development Core Team. R Development Core Team. R: A Language and Environment for 
Statistical Computing. (2.9.2). 2009. Vienna, Austria, R Foundation for Statistical Computing. 
 29.  Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjemdahl P: Platelet-leukocyte 
cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000;20:2702-2708. 
 30.  Grau AJ, Sigmund R, Hacke W: Modification of platelet aggregation by leukocytes in acute 
ischemic stroke. Stroke 1994;25:2149-2152. 
 31.  Marquardt L, Anders C, Buggle F, Palm F, Hellstern P, Grau AJ: Leukocyte-platelet aggregates 
in acute and subacute ischemic stroke. Cerebrovasc Dis 2009;28:276-282. 
 32.  Topakian R, King A, Kwon SU, Schaafsma A, Shipley M, Markus HS: Ultrasonic plaque 
echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neurology 
2011;77:751-758. 
 33.  Ritter MA, Jurk K, Schriek C, Nabavi DG, Droste DW, Kehrel BE, Bernd RE: Microembolic 
signals on transcranial Doppler ultrasound are correlated with platelet activation markers, but 
not with platelet-leukocyte associates: a study in patients with acute stroke and in patients with 
asymptomatic carotid stenosis. Neurol Res 2009;31:11-16. 
 34.  Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, Han Z, Tan KS, Ratanakorn 
D, Chollate P, Zhao Y, Koh A, Hao Q, Markus HS: Clopidogrel plus aspirin versus aspirin alone 
for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis 
(CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-
497. 
 35.  King A, Bath PM, Markus HS: Clopidogrel versus dipyridamole in addition to aspirin in 
reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 
2011;42:650-655. 
 36.  Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, Cleutjens KB, 
Heeneman S, Daemen MJ: Atherosclerotic plaque rupture: local or systemic process? 
Arterioscler Thromb Vasc Biol 2003;23:2123-2130. 
 37.  Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, King-Im JU, Li ZY, Brown AP, 
Kirkpatrick PJ, Gaunt ME, Gillard JH: Assessment of inflammatory burden contralateral to the 
symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-
enhanced MRI. Stroke 2006;37:2266-2270. 
 
 
